This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

PEB - Pacific Edge

Jump to new

System

Joined
27 June 2010
Posts
4,318
Reactions
364
Pacific Edge Limited is a cancer diagnostics company specialising in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.

Pacific Edge's products are built from their proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.

Their intellectual property covers the areas of bladder, gastric, colorectal and endometrial cancers and melanoma; however, their commercial focus is on bladder cancer products for the short to medium term. The Company's wider portfolio is expected to provide them with further options in the future.

It is anticipated that PEB will list on the ASX during September 2021.

Home | Pacific Edge

Innovative solutions for cancer diagnostics.
www.pacificedgedx.com
 
Pacific Edge is listed on the NZX Main Board and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited

Market cap is about NZ$1Billion

The ASX listing is pro forma

Listing date23 September 2021 #
Company contact detailshttps://www.pacificedgedx.com/
Ph: +64 3 479 5800
Principal ActivitiesDevelopment and deployment of specialist cancer diagnostics tools
GICS industry groupTBA
Issue PriceN/A
Issue TypeOrdinary Fully Paid Shares
Security codePEB
 
The ASX listing of NZ biotech Pacifc Edge (PEB) occurred at 11am today.... opened at $1.55 and holding around that price.
 
In the cap raise held at the same time as ASX listing, PEB has added 59,259,259 new shares ; Issue price per security NZ$1.35 or A$1.31. This is an additional 8.13% of share base.

There is also a Retail Offer just open, to raise up to a further NZ$20 million (A$19.4 million) (with ability to accept oversubscriptions). Each Eligible Shareholder will be entitled to apply for up to NZ$50,000 of new shares under the Retail Offer.

SP trading a bit above, still, at $1.43
 
and .... one to avoid

Bell Potter finally initiated research coverage, with a speculative buy recommendation at a 12-month price target of $1.10 a share.
Click to expand...

Which is a 35 per cent increase on the prevailing market price of 88c Gee, thanks guys. Why, 6 months ago, there was an...
$80 million equity raising ahead of a dual listing on the Australian Securities Exchange at $1.31.

The company had stockbrokers Bell Potter, Jarden and Forsyth Barr launch the deal
Click to expand...
 
Dona Ferentes said:
and .... one to avoid
.......
Click to expand...
watch out below.

Pacific Edge’s chief executive, Peter Meintjes, told investors he was “surprised” and “disappointed” after a US Medicare administrator, Novitas, determined the oncology product was “not considered medically reasonable and necessary”.

Mr Meintjes said the rejection appeared to “materially misunderstand” the role its Cxbladder tool plays in bladder cancer diagnostics.

This reduced the diagnostic group’s market value to $NZ97.3 million from $NZ401.1 million. Its ASX-listed scrip plunged 72.4 per cent to 10.5¢ from 38¢.

“Now that Novitas has codified their views in a finalised local determination coverage, we are able to consider and assess the potential necessary adjustments required to regain Medicare coverage,” chief medical officer Tamer Aboushwareb said.

... yeah, mebe.

Since listing ....
 
Pacific Edge has warned that proposed changes to US Food and Drug Administration guidelines could result in more red tape for its bladder cancer diagnostic device, Cxbladder.
 
Dona Ferentes said:
Pacific Edge has warned that proposed changes to US Food and Drug Administration guidelines could result in more red tape for its bladder cancer diagnostic device, Cxbladder.
Click to expand...
and that is why i avoid this sector , the FDA is a beast in it's own class

so i am guessing this test actually works in some cases ..
 
from 10c to 16c since this news of last week:


 
the ups and downs and ups


.
CXBLADDER INCORPORATED INTO AUA CLINICAL GUIDELINE
• New AUA microhematuria guideline incorporates language for urine-based biomarkers in appropriately counseled intermediate-risk patients
• Guideline specifically mentions Cxbladder Triage as the only urine biomarker with ‘Grade A’ evidence
• Intermediate-risk patients represent an estimated 70% of those presenting with
microhematuria

nh, nh
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...